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Abstract: Solid tumors are complex and unstructured organs that, in addition to cancer cells, also
contain other cell types. Carcinoma-associated fibroblasts (CAFs) represent an important population
in the tumor microenviroment and participate in several stages of tumor progression, including
cancer cell migration/invasion and metastasis. During peritoneal metastasis, cancer cells detach
from the primary tumor, such as ovarian or gastrointestinal, disseminate through the peritoneal
fluid and colonize the peritoneum. Tumor cells metastasize by attaching to and invading through the
mesothelial cell (MC) monolayer that lines the peritoneal cavity, then colonizing the submesothelial
compact zone where CAFs accumulate. CAFs may derive from different sources depending on the
surrounding metastatic niche. In peritoneal metastasis, a sizeable subpopulation of CAFs originates
from MCs through a mesothelial-to-mesenchymal transition (MMT), which promotes adhesion,
invasion, vascularization and subsequent tumor growth. The bidirectional communication between
cancer cells and MC-derived CAFs via secretion of a wide range of cytokines, growth factors and
extracellular matrix components seems to be crucial for the establishment and progression of the
metastasis in the peritoneum. This manuscript provides a comprehensive review of novel advances
in understanding how peritoneal CAFs provide cancer cells with a supportive microenvironment,
as well as the development of future therapeutic approaches by interfering with the MMT in
the peritoneum.
Keywords: mesothelial-to-mesenchymal transition; carcinoma-associated fibroblasts; peritoneal
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1. Introduction
The majority of tumors are confined to the organ where they first originated and are usually
treatable and curable with local therapy. However, several neoplasias are incurable due to
processes that govern the ability of cells to disseminate and implant in distant locations. Although
hematogenous and lymphatic dissemination are the most common routes for metastasis, tumors
originating adjacent to the peritoneal cavity, such as ovarian or colorectal cancer, frequently
disseminate via transcoelomic route to develop peritoneal metastases. Cancer cells detached from
the primary tumor are transported by peritoneal fluid to subsequently spread locally colonizing
the peritoneum [1,2]. This process is known as peritoneal carcinomatosis and signifies that the
disease is at advanced stage, is difficult to treat and, often, there is no prospect of cure. A
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common characteristic of abdominal cancers that progress with peritoneal metastasis is that they
generally evolve very rapidly and correlate with poor prognosis. The peritoneal cavity is the site
of metastases in up to 28% of recurrent endometrial cancers [3], 42% of colorectal cancers [4], 40%
of gastric cancers [5] and 70% of ovarian advanced cancers [2]. Surgery is inefficient to render
patients free of disease, resulting in low survival rates. This is in part due to the diffuse nature of
peritoneal metastases, which renders them generally intractable to surgical resection. Nowadays,
aggressive surgical tumor removal (tumor cytoreduction) coupled with hyperthermic intraperitoneal
chemotherapy (HIPEC) represents the cornerstone of advanced abdominal oncologic surgery. The
combination of both treatments seems to be encouraging and in colorectal and gynecological cancers
provides five-year survival rates of over 40% and 45%, respectively [6,7]. However, these are complex
therapies that require specialized technological facilities with highly qualified human resources
and the possibility of curing advanced stage intraperitoneal tumors still remains limited [8]. Part
of this problem derives from the fact that the pathogenesis of peritoneal carcinomatosis is not
well understood. Therefore, to design new therapeutic approaches it is necessary to improve our
knowledge of the mechanisms implicated in tumor progression in the peritoneum. This manuscript
focuses on providing a comprehensive review of novel advances in understanding how the peritoneal
stroma and, in particular, carcinoma-associated fibroblasts (CAFs) provide cancer cells with a
supportive microenvironment for peritoneal implantation. In this context, the recent description of
the mesothelial origin of peritoneal CAFs via mesothelial-to-mesenchymal transition (MMT) opens a
new research line to be considered in the treatment of peritoneal metastases that frequently occur in
patients with abdominal cancers [9].
2. The Seed and Soil Theory in Peritoneal Metastasis
Metastasis remains the major cause of death for cancer patients. Cancers that metastasize are
generally more difficult to treat and have a worse prognosis than those that remain at the site
of origin [10]. During peritoneal metastasis, cancer cells leave the primary tumor to colonize the
secondary organ (peritoneum) where they develop into metastatic lesions. The peritoneum is a
well-known metastatic site for several intra-abdominal malignancies, such as ovarian, colon, gastric,
pancreatic, endometrial and rectal cancer. However, the specific site of distant metastasis is not simply
due to the intrinsic features of the primary tumor, its anatomic location or proximity to secondary
sites but, rather, it involves interactions between tumor cells and the local microenvironment at the
secondary site. Therefore, in the establishment of metastasis, the properties of the tumor are as
important as the metastatic niche. In 1899, Stephen Paget suggested the “seed and soil” hypothesis to
explain how sites where metastases occur are defined not only by the tumor cell (“seed”) but also the
microenvironment of the secondary metastatic site (“soil”). Accordingly, metastases are influenced
by innumerable factors and complex cellular interactions between the seed and the soil [11,12]. In the
case of peritoneal carcinomatosis, the metastatic niche is composed of the surface of the peritoneum
overlying the abdominal cavity. The organization of the peritoneum is simple: a single layer of
mesothelial cells (MCs) lines a compact region that is composed of connective tissue with a few
fibroblasts, mast cells, macrophages and vessels [13]. The “seed and soil” mechanism seems to
be especially relevant in peritoneal metastasis, since profound modifications of the surrounding
metastatic stroma have been recently described during the processes of attaching to and invading
through the peritoneal membrane.
The transformed peritoneal microenvironment forms a suitable niche for peritoneal metastasis,
promoting the progression of secondary tumors [9]. Therefore, it is tempting to speculate that
future therapeutic options for the treatment of peritoneal metastasis may lie in modulating the
interaction between the tumor and the mesothelium by regulating the molecules that modify the
metastatic microenvironment.
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3. Carcinoma-Associated Fibroblasts in the Peritoneum
Currently, there is an increased understanding of the processes that govern the malignant
transformation of cells. It is known that tumor development is mainly associated with the
accumulation of multiple genetic and epigenetic alterations in cancer cells which pave the way for
the transformation of a normal cell into a malignant cell [14]. However, tumors are highly complex
organs composed of different cell types. Cancer tissue consists of both tumor cells and stromal
cells surrounded by an extensive extracellular matrix (ECM). The stromal component constitutes a
large part of most solid tumors and includes multiple cell types, such as mesenchymal, vascular
and immune cells, that converge to support a tumorigenic niche. The development of the tumor
microenvironment is triggered by signaling molecules secreted by cancer cells that corrupt the
adjacent normal tissue to create an “activated” stroma [15].
The peritoneal pre-metastatic niche is basically composed of MCs, fibroblasts, endothelial cells,
adipocytes and immune cells, including macrophages. However, during peritoneal metastasis
normal mesothelium is replaced by a strong stromal reaction (desmoplasia) characterized by the
accumulation of activated fibroblasts (myofibroblasts) [16]. The exacerbated accumulation of
activated fibroblasts in the peritoneum has been previously described in other fibrotic disorders
including peritoneal dialysis-induced fibrosis [17] and abdominal adhesions [18]. In the cancer
stroma, it has become clear that activated fibroblasts are prominent modifiers of tumor progression
towards advanced stages and their presence is often associated with poor clinical prognosis for
oncology patients. They are known as carcinoma-associated fibroblasts (CAFs)—among other terms,
such as tumor-associated fibroblasts or reactive stromal fibroblasts—and represent a predominant
population in the tumor architecture [19]. CAFs share characteristics with myofibroblasts, such as
the expression of alpha-smooth muscle actin (α-SMA) [20–22], fibroblast activation protein-alpha
(FAP-α) [23,24] and fibroblast-specific protein 1 (FSP1) [25,26]. They are activated fibroblasts capable
of producing a wide array of cytokines, growth factors, proteases, and ECM components, thereby
contributing to increasing the motility and invasive potential of tumor cells. Additionally, CAFs have
been widely implicated in promoting tumor angiogenesis, which is necessary for cancer survival and
metastasis towards secondary organs [27,28].
4. Mesothelial Cells as Source of Carcinoma-Associated Fibroblasts
An important effect of the tumor nesting into the peritoneal membrane is the exacerbated
accumulation of CAFs [16]. However, the multiple origins of peritoneal CAFs are still debated
today. It has been proposed that CAFs may derive from different sources depending on the
surrounding tumor metastatic niche. Additionally, there is emerging evidence that the origin
of CAFs may vary between cancer types and within different areas of individual tumors [29].
The activation of resident fibroblasts was considered the main origin of CAFs in the tumor
microenvironment [30]. However, recent studies have revealed that bone marrow-derived stem
cells (fibrocytes) are integrated into tumor stroma and differentiate into myofibroblasts. Cancer
cells can also undergo an epithelial-to-mesenchymal transition to acquire myofibroblast properties,
although their contribution to the CAF population is small [29,31,32]. In addition, it has been shown
that endothelial cells, through an endothelial-to-mesenchymal transition, may also be a source of
CAFs [33,34]. Moreover, MCs have been traditionally considered as an important source of activated
fibroblasts in pathologies that present fibrosis. The presence of MCs converted into myofibroblasts
though MMT was first described in the peritoneum of peritoneal dialysis patients [35]. Emerging
evidence has subsequently revealed that MMT is an important event in numerous fibrogenic
disorders such as idiopathic lung fibrosis [36], liver fibrogenesis [37] and myocardial infarction
scars [38,39]. However, until recently, it was unclear whether normal MCs convert into CAFs during
peritoneal carcinomatosis. The presence of a sizeable subpopulation of CAFs originated from MCs
through MMT in patients with malignant peritoneal disease was first reported in 2013 [9]. Evidence
of MMT was based on the immunohistochemical detection of specific mesothelial markers (calretinin,
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cytokeratins, WT1, mesothelin) in submesothelial myofibroblasts (α-SMA) within or near peritoneal
implants from ovarian and colon cancers. Supporting these data, FAP-positive mesothelium in gastric
cancer patients has been associated with advanced stage disease, peritoneal dissemination and poor
survival [40].
Briefly, during MMT the MCs lose their epithelial characteristics to acquire a myofibroblastic
phenotype [35,41]. MMT is a complex and stepwise process that involves alterations in the cellular
architecture and a deep molecular reprogramming. The MMT starts with the dissociation of
intercellular junctions, due to downregulation of intercellular adhesion molecules, and with the loss
of microvilli and apico-basal polarity. Then, cells adopt a front-to-back polarity, acquire α-SMA
expression and increase their migratory capacity. In the last stages of the MMT, the cells acquire the
capacity to degrade the basement membrane and to invade the fibrotic compact zone [42]. During
the end stages of myofibroblast conversion, MCs are able to produce a large amount of extracellular
matrix components and synthesize a wide range of inflammatory, profibrotic and angiogenic factors
that may contribute to structural and functional changes in the peritoneal membrane [35,41,43–46].
5. Mesothelial-to-Mesenchymal Transition Promoting Stimuli in Peritoneal Metastasis
Peritoneal metastasis is a consequence of a sequential process that can be briefly summarized
in three principal steps: (a) Tumor cells trigger an early MMT and adhere to mesothelial monolayer;
(b) MMT progresses and tumor cells invade through the peritoneum; (c) Mesothelial-derived CAFs
accumulate in the submesothelial compact zone, where they provide the tumor with the adequate
blood support and ECM components to progress. Therefore, the myofibroblastic conversion of MCs
plays an important role in both the initial stages of peritoneal metastasis and the growth of the
secondary tumor implants [9].
In the context of peritoneal metastasis, the promoting stimuli able to induce the mesenchymal
conversion of MCs are still not completely characterized. An important characteristic of patients
that develop peritoneal carcinomatosis is the presence of ascites, the pathologic accumulation
of fluid in the peritoneal cavity. In this context, ovarian cancer can account for up to 47%
of malignant ascites, followed by other gastrointestinal cancers; all of them correlating with
poor survival, gastrointestinal tumors being the most severe [47–49]. Malignant ascitic fluid is
composed of cytokines, chemokines, growth factors, exosomes and suspended cells that vary in
proportion between patients: leukocytes, MCs, macrophages, tumor cells and plasma cells [50–54].
Many cytokines and growth factors are present in high concentration in malignant ascitic fluid,
including transforming growth factor-beta1 (TGF-β1), tumor necrosis factor-alpha (TNF-α), vascular
endothelial growth factor (VEGF), hepatocyte growth factor (HGF), interleukin-1 beta (IL-1β),
interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) [55–62]. Interestingly, many of
these soluble mediators, such as TNF-α, IL-6, TGF-β1 and IL-1β have important pro-inflammatory
roles in the peritoneal environment and, as a consequence, have been widely implicated in
fibrosis by stimulating fibroblast proliferation [63,64], ECM component deposition, and MMT
induction [41,65]. Therefore, it is tempting to speculate that in peritoneal metastasis diverse cytokines
could be contributing to the modification of the mesothelial surface in order to initialize tumor
implantation [66–68]. To this effect, elevated IL-6 and TNF-α in ascites of patients in late stages of
ovarian cancer are considered independent predictors of poor survival [67,69].
Among the growth factors accumulated in ascites, HGF has recently been implicated in the
implantation of endometrial cells [70] and ovarian cancer cells [71] in the peritoneum via a MMT.
Regarding this idea, in vitro experiments have shown that ovarian cancer ascites enhances the
migration and invasion of both patient-derived peritoneal MCs [55] and ovarian cancer cells [56]
through HGF-dependent mechanisms.
TGF-β1 is a master molecule that accumulates in the ascitic fluid and presents both anti- and
pro-tumoral effects [72,73]. However, TGF-β1 is also a prototypical inducer of MMT and is a key
factor in the activation of peritoneal fibroblasts, regardless of their origin [74]. The activity of TGF-β1
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on stromal cells has been reported to increase the efficiency of organ colonization by tumor cells [23].
Thus, it can be speculated that targeting the TGF-β1 pathway could interfere with the accumulation
of peritoneal CAFs [75]. A large proportion of tumors, including colorectal and ovarian cancer,
display mutational inactivation of the TGF-β1 pathway yet, paradoxically, they are characterized
by elevated TGF-β production [23]. In fact, in vitro experiments have showed that carcinoma cells
secrete high concentrations of TGF-β1, inducing the mesenchymal conversion of MCs. In addition,
blockade of the TGFβ type I receptor prevents the conversion of MCs into CAFs mediated by tumor
conditioned media [9]. Similarly, Miao et al. demonstrated that gastric cancer cells expressing high
levels of TGF-β1 induce both downregulation of E-cadherin and upregulation of α-SMA in the
mesothelium [76].
One general characteristic of tumors is their ability to release vesicular portions of membrane
material, termed exosomes, which were initially described by Thery et al. [77]. Exosomes serve as
vehicles that transfer proteins, as well as RNA (mRNA and miRNA), between cells and have been
found in malignant ascites from ovarian and gastrointestinal cancer patients [52,78–80]. While the
precise mechanism of communication between cancer and MCs in the peritoneum remains unclear,
there is growing evidence that exosomes may serve as prognostic/diagnostic indicators of peritoneal
dissemination. Regarding this idea, exosomes derived from colorectal cancer ascites contain proteins
that may promote tumor progression via angiogenesis, disruption of epithelial cell polarity, immune
modulation, tumor growth and invasion [52]. On this note, ovarian cancer exosomes administered to
mice prior to tumor cell injection have been shown to induce a more aggressive disease and to increase
tumor growth [81]. Of the miRNAs contained in exosomes, miR-21, known for its pro-oncogenic
activity [82], is present in both ovarian [79] and gastric [80] cancer ascites. Expression of miR-21
in exosomes is associated with pathways related to TGFβ signaling, ECM-receptor interaction,
mesothelial clearance and worse prognosis/diagnostic value; thus, providing a novel approach for
early diagnosis of peritoneal dissemination [80,81]. In addition, Vaksman et al. concluded that the
effect of exosomes is mainly exerted on MCs, rather than on tumor cells, and higher miRNA levels
are associated with poor survival [81]. These data suggest that exosomes may play a role in modifying
the metastatic niche to favor peritoneal dissemination.
6. Implication of Mesothelial-Derived Carcinoma-Associated Fibroblasts in Adhesion, Invasion
and Progression of Peritoneal Metastasis
Independently of the MMT-promoting factors that could initiate peritoneal metastasis, different
hypotheses have tried to explain how malignant cells attach to the peritoneal membrane during
the earliest stages. Initially, it was believed that MCs were simply victims of tumor aggression to
the peritoneum [83,84]. Some experimental models proposed that intraperitoneal cancer spheroids
gain access to the submesothelium by exerting force to clear MCs [85–87]. Subsequently, there was
speculation that cancer cells do not adhere to the MCs but, rather, to the connective tissue under
the MCs. In this context, “milky spots” are omental areas in which the ECM is exposed and they
have been identified as the preferred sites for peritoneal colonization [88]. However, “milky spots”
are structures essentially comprised of an accumulation of immune cells and capillaries where the
triggering of an inflammatory response can influence peritoneal metastasis, transforming the initial
pattern of the “milky spot” attachment into a widespread pattern of dissemination [89]. On the other
hand, in vitro adhesion experiments have demonstrated that cancer cells bind better to mesenchymal
than to epithelial-like MC monolayers [9,40]. Scanning electron microscopy analysis revealed that
the enhanced adhesion of tumor cells to mesenchymal MCs is not due to a mere exposure of the
underlying matrix but rather to an increased cell-cell interaction [9]. De Vlieghere et al. have recently
shown that CAFs are able to selectively capture floating cancer cells, delaying tumor adhesion
to the natural mesothelial niche [90]. Then, MMT may play an important role in conferring an
advantage on metastatic cells for attachment to the peritoneal membrane [9]. A wide range of
adhesion molecules including CD44, CA125/MUC16, ICAM-1 or VCAM-1 are reportedly involved in
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the binding of cancer cells to the mesothelium [91–97]. The molecular mechanisms that mediate the
tumor-mesothelium interaction during the mesenchymal conversion of MCs would require further
analysis. However, a growing body of experimental evidence on adhesion concurs that, at initial
stages of peritoneal metastasis, MMT enhances the binding of cancer cells on the peritoneum in
a β1-integrin-dependent manner [9,98,99]. In agreement with this notion, it has been reported
that cleavage of MC-associated matrix proteins fibronectin and vitronectin by MMP-2 enhances
integrin-mediated carcinoma-mesothelium attachment [100,101]. Furthermore, blocking antibodies
or siRNA directed against either ICAM-1 [102], VCAM-1 [103], fibronectin [101] or their integrin
ligands significantly decrease the adhesion and invasion of ovarian cancer cells through the MC
monolayer, and dramatically reduced metastases in a mouse model [104].
In a second stage of peritoneal metastasis, tumor cells reach the submesothelial compact zone.
Histological analysis has shown that MC-derived CAFs accumulate in areas with micrometastases but
not in tumor-free regions, suggesting that tumor cells promote the invasion of adjacent MCs. Indeed,
in vitro invasion assays suggest that carcinoma cells embedded in a matrix enhance the invasive
capacity of MCs. The enhanced invasion triggered by tumor cells seems to be a consequence of the
acquisition of a mesenchymal phenotype by MCs [9]. In fact, during the MMT process, MCs increase
their migration/invasion capacity [105]. Therefore, MCs that have invaded the matrix, in turn, further
promote invasion by carcinoma cells. Mesenchymal MCs and carcinoma cells seem to establish a
feed-forward cycle by mutually stimulating their invasive capacity. Accordingly, MCs have been
considered as the advancing front of the tumor in the processes of peritoneal carcinomatosis [106,107].
MCs behave in a similar fashion to resident fibroblasts in terms of the induction of carcinoma cell
invasion in vitro. It has been shown that normal omentum fibroblasts induce the adhesion and
invasion of carcinoma cells in 3D culture models [101,108]. On the other hand, Cai et al. reported that
activated fibroblasts (either CAFs isolated from omentum of patients with ovarian cancer metastasis
or normal omentum fibroblasts stimulated with TGF-β1) have stronger effects on carcinoma cell
attachment and invasion than normal fibroblasts [109]. Furthermore, the growth dynamics of
cancer xenografts produced in response to intraperitoneal co-injection of omental MCs with either
ovarian [110] or gastric [111] cancer cells was remarkably greater than for implantation of cancer
cells alone.
Therefore, in stark contrast to initial impressions, it is now accepted that MCs are not a passive
barrier that prevents the progression of the tumor into the peritoneum, but are able to actively
promote the process of adhesion to and invasion through the peritoneum.
In order for tumor cells to migrate and/or invade through the colonized organs, ECM disruption
is crucial [112]. Matrix metalloproteinases (MMP) are known to be important molecular players in
the physiological processes of cancer progression by facilitating angiogenesis and tumor invasion
through matrix degradation [113–115]. In this context, CAFs have been widely implicated in the
remodeling of the ECM components through MMPs to consequently favor cancer invasion [116,117].
It is well known that, at an intermediate stage of epithelial-to-mesenchymal transition, cells acquire
the capacity to degrade the basement membrane and to invade the fibrotic stroma by upregulating
the expression of MMPs [42]. In MCs, the expression of MMP-2 and MMP-9 increases in response
to MMT-inducing stimuli such as TGF-β [118] or TNF-α [119]. Interestingly, both of these MMPs
can activate the latent form of TGF-β [120]. In addition, fibroblasts in omentum that have
been activated by tumor cells have been shown to promote ovarian invasiveness via MMP-2
overexpression [109]. Similarly, exosomes of ovarian cancer ascites contain MMP-2, MMP-9 and
urokinase-type plasminogen activator (uPa), all of them able to degrade the ECM, facilitating invasion
and dissemination of tumor cells [53]. Additionally, expression of VEGF by ovarian cancer cells is
involved in transforming the ECM by stimulating MMP-9 expression at the tumor site [121]. With
regard to the peritoneal environment, MCs undergoing a MMT contribute to the deposition of ECM
components, including fibronectin and collagen I [9]. Therefore, although further analysis is required,
we could speculate that, by increasing ECM deposition and MMP expression, mesothelial-derived
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CAFs regulate their own invasive capacity while helping to provide the appropriate ECM scaffold for
cancer cells to survive in the metastatic niche [122–125].
CAFs in the tumor compartment have been implicated in promoting the growth and/or
proliferation of cancer cells, ensuring their survival at the colonized organ. Although,
mesothelial-derived CAFs have not yet been implicated in directly augmenting tumor growth, some
authors have suggested that MCs establish communication with the tumor by secreting proliferating
stimuli or by direct cell–cell contact which, in turn, stimulate proliferation of cancer cells and drive
peritoneal dissemination [110,111].
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Figure 1. Model for transformation of the pre-metastatic niche by mesothelial-to-mesenchymal
transition in the peritoneum: (1) Cancer cells at the primary site secrete an array of exosomes,
cytokines, chemokines and growth factors that accumulate in the ascitic fluid. Some of these
molecules, such as transforming growth factor-beta1 (TGF-β1) or hepatocyte growth factor
(HGF), induce changes in the mesothelial cells (MCs), triggering a mesothelial-to-mesenchymal
transition (MMT), through which they lose apico-basal polarity and cell-cell adhesion, and acquire
myofibroblastic properties. (2) Cancer cells adhere via β1 integrins to the MCs that line the
peritoneum. This adhesion is increased when a MMT has taken place. (3) In later stages of MMT,
MCs have converted into carcinoma-associated fibroblasts (CAFs) that represent the invasion front
into the stroma, followed by cancer cells. (4) After invading, MC-derived CAFs accumulate in
the peritoneal stroma. (5) CAFs produce factors that affect peritoneal implant progression: they
induce angiogenesis via secretion of VEGF, among other factors; they transform the extracellular
matrix (ECM) by producing collagen, fibronectin and other structural proteins, and they remodel
the ECM via matrix metalloproteinases (MMPs); they also stimulate proliferation of cancer cells.
(6) The metastatic niche in the peritoneum is created as a result of the clearance of the MC monolayer,
myofibroblast conversion of MCs, invasion of MCs and cancer cells, accumulation of CAFs, increased
vascularization, ECM remodeling and proliferation of cancer cells. (7) Cancer cells in the new site,
together with CAFs, will continue to produce factors that modify the stroma and induce changes in
both cancer cells and MCs, thereby creating a positive feedback loop.
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At advanced stages of peritoneal metastasis, vascularization is necessary for tumor progression.
Angiogenesis is also influenced by the organ microenvironment and is the result of an imbalance
between positive and negative angiogenic factors released by tumor and host cells into the
microenvironment of the neoplastic tissue [126]. In ovarian cancer progression in particular, the key
role of vascular endothelial growth factor (VEGF) has been well established and is correlated with
decreased overall survival [127]. Interestingly, VEGF appears as one of the most induced factors in
MCs transformed into myofibroblasts [128,129]. The fact that the MCs that have undergone MMT
express high amounts of VEGF suggests that peritoneal CAFs may play an important role in tumor
vascularization [130]. In this respect, prominent new vessel formation has been observed in the
peritoneal areas of human biopsies harboring tumor cells and MC-derived CAFs when compared
to tumor-free regions. Indeed, the use of a mouse model of peritoneal dissemination confirmed
increased angiogenesis at tumor implant sites [9]. In fact, Sako et al. showed that peritoneal
dissemination of gastric cancer was significantly suppressed when adenovirus expressing a soluble
form of the VEGF receptor Flt-1 was administered intraperitoneally to mice [131].
In summary, peritoneal metastasis is the result of a close multi-directional communication
between cancer cells, MCs and CAFs. Tumor cells are able to trigger the myofibroblastic conversion
of MCs via MMT, thus increasing adhesion to and invasion through the peritoneum. Finally,
mesothelial-derived CAFs accumulated in the submesothelial compact zone provide the tumor with
the adequate blood support, ECM components and/or proliferating signals to progress to advanced
stages (Figure 1).
7. Mesothelial-to-Mesenchymal Transition as a Potential Therapeutic Target in
Peritoneal Metastasis
CAFs’ proven tumor-promoting capacities have raised interest in exploiting them as drug targets
for anticancer therapy [132]. Undoubtedly, the recent description of the origin of CAFs from the
adjacent mesothelium via MMT could point to an alternative target in the treatment of metastases that
disseminate via the peritoneum, since this process can be easily modulated. Therapeutic strategies
could be designed to avoid the accumulation of mesothelial-derived CAFs in the compact zone by
preventing or reverting the MMT itself, by reducing the MMT-promoting stimuli in the peritoneal
cavity, and/or by treating the MMT-associated effects, such as tumor cell adhesion and invasion,
ECM accumulation or pro-angiogenic factor synthesis.
MMT results from molecular signals accumulated in the peritoneal cavity. These include
inflammatory cytokines and growth factors [133]. Therapeutic approaches could be directed
to interfere with or modify the upstream MMT-promoting stimuli operating in the peritoneal
cavity prior to tumor adhesion to the mesothelium. Regarding this idea, TGF-β1 is a master
molecule in the induction of MMT and is highly accumulated in malignant ascitic fluids. It
has been demonstrated that interfering with the TGF-β1 pathway in vitro prevents the conversion
of MCs into CAFs [9]. In vivo experiments also showed that using a TGF-β1 blocking agent
prevented peritoneal dissemination of gastric cancer cells by preserving the mesothelial monolayer
structure [76]. Although further studies are needed in this regard, it should be considered that agents
directly blocking TGF-β1 cannot be easily employed in the clinical practice, at least for long-term
treatments, because TGF-β1 has important modulating functions of the immune and inflammatory
responses [133,134]. Hence, the molecular studies of the downstream TGF-β1 Smad-dependent
signaling pathways involved in MMT could provide more specific strategies for the preservation
of peritoneal membrane with fewer side effects. In this context, the use of an endogenous negative
regulator of this process, bone morphogenetic protein (BMP)-7, has been shown to block/reverse
MMT in vitro, ex vivo and in vivo, reducing fibrosis, angiogenesis, invasion and the acquisition of a
mesenchymal phenotype by MCs [135,136]. The molecular characterization of the TGF-β1-mediated
Smad-independent signaling involved in the prevention/reversion of MMT could provide a wide
range of possible molecular targets with roles in regulating the MMT, such as transforming growth
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factor-activated kinase 1 (TAK1) [105], extracellular-signal-regulated kinases (ERKs)-1/2 and the
nuclear factor-κB (NF-κB) [137–139].
As discussed above, MMT could result from molecular inflammatory signals associated with
the intraperitoneal ascitic environment. Previous studies of MMT in peritoneal dialysis have
demonstrated that the use of pharmacological agents that target inflammation preserve the peritoneal
membrane. Celecoxib is a potent anti-inflammatory drug whose mechanism of action is based on the
inhibition of cyclooxygenase (COX)-2, which is expressed at high levels by MCs that undergo MMT.
COX-2 has been widely implicated in inflammatory responses, as well as in fibrotic and angiogenic
processes in animal peritoneal dialysis models [140,141]. Interestingly, expression of COX-2 is also
elevated in tumor cells from colorectal and ovarian carcinomas [142,143]. Multiple clinical studies
show the effectiveness of specific inhibitors of COX-2 in preventing or delaying re-occurrence of
cancer, including metastases, in high risk patients [144–147].
Targeting adhesion of cancer cells to the mesothelium could also be considered as a therapeutic
strategy for treatment of peritoneal metastasis, given that the use of blocking antibodies or siRNA
against α5 and/or β1 integrins has shown significantly reduced attachment, tumor burden and
peritoneal metastasis in mouse models [104,148–151]. Interestingly, it has been reported that the
oxidative stress that accompanies senescent MCs may facilitate the adhesion and dissemination of
cancer cells; and the use of an antioxidant significantly reduced this attachment [95,152]. Similarly to
the MMT, senescence mediates the interaction of tumor cells and MCs via binding of α5β1 integrin
to fibronectin, respectively [152]. Additionally, higher production levels of TGF-β1 by MCs have
been associated with oxidative stress, but also with age of the patients, suggesting there may be an
accumulation of senescent MCs in vivo [153].
An alternative approach could be the use of pharmacological agents that preserve the
mesothelium. With regard to ovarian cancer, hormone treatment with Tamoxifen is often used in
conjunction with chemotherapy and other therapies [154]. Tamoxifen is a synthetic modulator of the
estrogen receptor that is known to act in peritoneal tissue. Its efficacy in preserving the peritoneal
structure was tested in a mouse model of peritoneal dialysis, where it reduced peritoneal thickness,
angiogenesis and invasion of the compact zone by transdifferentiated MCs. The mechanism by
which Tamoxifen inhibits the invasion capacity of mesenchymal-like MCs involves the inhibition of
matrix metalloproteinase (MMP)-2 [155]. Furthermore, blocking of MMP-2 in MCs has been shown
to reduce invasion by gastric cancer cells in vitro [156]. On this note, adhesion of ovarian cancer cells
to the mesothelium is mediated by MMPs [85,101] and their inhibition in ovarian cancer cells prior
to inoculation in mice resulted in reduced metastasis. Therefore, strategies directed towards MMP
inhibition would also be of interest in the treatment of peritoneal metastases and may prevent the
accumulation of MC-derived CAFs in the submesothelial stroma [157–159].
Recently, it has been demonstrated that the invasion capacity of MCs that have undergone a
MMT is governed, at least partially, by the VEGF/VEGF receptors/co-receptors axis. It was shown
that blocking antibodies directed against VEGF or the co-receptor neuropilin-1 efficiently reduced
the invasion of MCs in vitro [128]. With regard to VEGF, its enhanced expression has been identified
as one of the most evident effects associated to MMT during peritoneal metastasis [9]. Therefore,
therapeutic intervention may also be directed at preventing peritoneal tumor vascularization
via interrupting VEGF expression or its effects on the stromal endothelial cell [160]. Various
anti-angiogenic therapies directed against VEGF or its receptors are presently being considered for the
treatment of advanced abdominal cancers [161,162]. The use of Bevacizumab, a monoclonal antibody
targeting VEGF, showed an improvement of patient survival in both colorectal [163] and ovarian
cancer [164].
It is important to note that reports of MMT in peritoneal carcinomatosis are very recent. Specific
treatments still require development; however, therapeutic options for interfering with the MMT in
peritoneal dialysis could be considered for the metastasis scenario, since the effects of MMT (MC
2002
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invasion, fibroblast accumulation, ECM deposition and angiogenesis) in the peritoneum seem to be
similar in both pathologies.
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